Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by D. Cunningham
Marshals down Falcons in five-inning rout
On Tuesday night, the Marshall County Marshals returned to Preston Cope Field after a two-game road stretch, where they played host to the Hickman County Falcons. The Marshals were riding high coming into Tuesday’s action, having won three straight games, dating back to April 19. The Falcons entered play on the opposite side of the same coin, looking to snap a three-game skid at the Marshals’ expense.
Biomarker analyses of second-line ramucirumab in patients with advanced gastric cancer from RAINBOW, a global, randomized, double-blind, phase 3 study
1. Introduction Worldwide cancer statistics record gastric/gastroesophageal junction (GEJ) cancer as a major cause of cancer-related deaths. About 1 million new cases of gastric cancer occurred in 2012, along with hundreds of thousands of new GEJ cancers, two-thirds with locally advanced or metastatic disease [1x[1]Ferlay J, Soerjomataram I, Ervik M et al. GLOBOCAN 2012 v1.0, estimated cancer incidence, mortality, and prevalence worldwide in 2012: IARC CancerBase No.11.
Third line treatment of advanced oesophagogastric cancer: A critical review of current evidence and evolving trends
Publication History Published online: October 17, 2018Accepted: October 14, 2018; Received in revised form: October 11, 2018; Received: August 8, 2018;
Investigating the feasibility of precision medicine in gastrointestinal cancers
Background: Molecular characteristics of patients' (pts) tumours can determine suitability for targeted drugs, but many variants are only seen in a small percentage of pts. Targeted next generation sequencing (NGS) can be used to screen tumours for multiple variants and therefore facilitate precision medicine, but details are lacking on the practicality of this approach. Methods: The FOrMAT study (ClinicalTrials.gov identifier NCT02112357) is a single-centre study in pts with advanced GI cancer.
KRAS mutations in circulating tumour DNA (ctDNA) in MRI-defined, high-risk, locally-advanced rectal cancer (LARC) patients (pts) from the EXPERT-C trial
Background: Although the potential of detecting ctDNA in solid tumours has been increasingly reported, there are limited data in LARC. We sought to investigate frequency and relevance of KRAS mutations in ctDNA in a randomised phase II trial of CAPOX followed by chemoradiotherapy, surgery and adjuvant CAPOX ± cetuximab in high-risk LARC. Methods: RAS (exon 2-4) mutations were previously analysed in the biopsy and resection samples using standard sequencing techniques.
Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Almost one million (951 600) new cases of gastric cancer were diagnosed globally in 2012, resulting in ∼723 100 deaths [1]. Of these ∼140 000 cases and ∼107 000 deaths occurred in Europe [2]. Gastric cancer displays significant global variation in incidence; the highest rates are seen in Eastern Asia, Eastern Europe and South America, with lower rates in North America and Western Europe.
O-007Biomarker analyses of second-line ramucirumab in patients with advanced gastric cancer from RAINBOW, a global, randomized, double-blind, phase 3 study
Introduction: Adding ramucirumab to paclitaxel in the RAINBOW trial led to significant improvements in overall survival (OS), progression-free survival (PFS), and response rate when compared to placebo and paclitaxel (Wilke H, et al. Lancet Oncol. 2014;15(11):1224-35). Plasma markers were evaluated for association with efficacy outcomes with the intention of identifying potential predictive or prognostic biomarkers.
PD-024Retrospective analysis of quality of life and early tumour shrinkage during first-line FOLFOX4 ± panitumumab in RAS wild-type metastatic colorectal carcinoma
Introduction: Metastatic colorectal cancer (mCRC) is rarely curable. Prolonging survival and maintaining or improving quality of life (QoL) are therefore key treatment goals. Achieving tumour shrinkage is also an important goal in these patients, as it can reduce tumour burden and increase the chance of surgical resection. In particular, early tumour shrinkage (ETS) may rapidly relieve tumour-related symptoms and provide an early indication of sensitivity to treatment.
PAN-EX: a pooled analysis of two trials of neoadjuvant chemotherapy followed by chemoradiotherapy in MRI-defined, locally advanced rectal cancer
Results A total of 269 patients were included. Of these, 91.1% completed NACT, 88.1% completed CRT and 240 (89.2%) underwent curative surgery (R0/R1). After a median follow-up of 71.9 months, 5-year progression-free survival (PFS) and OS were 66.4% and 73.3%, respectively. In the group of R0/R1 resection patients, 5-year relapse-free survival (RFS) and OS were 71.6% and 77.2%, respectively, with local recurrence occurring in 5.5% and distant metastases in 20.6% of cases.
PAN-EX: A pooled analysis of two trials of neoadjuvant chemotherapy followed by chemoradiotherapy in MRI-defined, locally advanced rectal cancer
Results 269 patients were included. Of these, 91.1% completed NACT, 88.1% completed CRT and 240 (89.2%) underwent curative surgery (R0/R1). After a median follow-up of 71.9 months, 5-year progression-free survival (PFS) and OS were 66.4% and 73.3%, respectively. In the group of R0/R1 resection patients, 5-year relapse-free survival (RFS) and OS were 71.6% and 77.2%, respectively, with local recurrence occurring in 5.5% and distant metastases in 20.6% of cases.
Gastric cancer: ESMO-ESSO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up
In 2012, there were ∼140 000 new cases of gastric cancer diagnosed across all European countries, making it the sixth commonest cancer diagnosis. Perhaps more importantly, it remains the fourth commonest cause of cancer-related death, being responsible for ∼107 000 deaths annually [1]. Despite a gradual decline in the worldwide incidence of gastric cancer, there has been a relative increase in the incidence of tumours of the oesophago-gastric junction (OGJ) and gastric cardia.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with D.
Contact D., search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack